Short answer
ANGIODYNAMICS INC (ANGO) filed its Q3 2026 10-Q quarterly report on Oct 8, 2026 for the quarter ended Aug 31, 2026. Quarterly revenue was $81M (up 6.9% year over year) with net income of −$7M.
Q3 2026 key financials · XBRL
- Revenue
- $81M
- +6.9% YoY
- Net income
- −$7M
- +34.9% YoY
- Operating margin
- -9.0%
- Gross margin
- 59.4%
- EPS (diluted)
- −$0.17
- +34.6% YoY
Source: XBRL data from the ANGIODYNAMICS INC (ANGO) Q3 2026 10-Q on SEC EDGAR. USD.
ANGIODYNAMICS INC Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $80.9M, up $5.2M or 6.9% YoY from $75.7M
- Gross margin 59.4% vs 55.3% YoY, Med Tech margin 66.2% vs 62.2%
- Med Tech strongest, revenue up 13.2% to $39.9M; Med Device weakest, up 1.4% to $41.0M
- Cash $34.0M vs $53.9M at May 31; operating cash use $15.3M, Auryon placements $2.8M
- Headwinds: inflation, tariffs, labor shortages, supply-chain challenges, backlog; liquidity sufficient for at least 12 months
Risk Factors
- No material changes to fiscal 2026 10-K risk factors
- Legal risk: approximately [number obscured] port product-liability claims remain pending
- Regulatory risk: FDA actions or changing medical-device regulations could delay product clearances or approvals
- Operational risk: manufacturing, supply-chain, labor, inflation and tariff pressures could disrupt production and margins
- Financial risk: cash declined to $34.0 million after $15.3 million operating cash outflow; no revolving debt outstanding
- Currency risk: 2.3% of sales denominated in foreign currencies, with no comparable foreign-currency expenses
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ANGIODYNAMICS INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.